Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanhuangjingshimingwan in Wet AMD
NCT04486963Phase 2Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in exudative macular degeneration comparing Sanhuangjingshimingwan Group with Placebo Group (2 arms). Primary endpoint: The average number of reinjections at 24 weeks. Started Jul 2020; status: completed.
02
Drugs
Sanhuang Jingshiming
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04486963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486963.